Microbot Medical Files Definitive Proxy Statement

TL;DR

Microbot Medical filed its proxy statement. Vote your shares!

AI Summary

Microbot Medical Inc. filed a definitive proxy statement (DEF 14A) on November 6, 2024. This filing is related to the company's annual meeting and likely concerns the election of directors, executive compensation, and other corporate governance matters. The company, previously known as STEMCELLS INC and CYTOTHERAPEUTICS INC/DE, is incorporated in Delaware and operates in the surgical and medical instruments sector.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership, compensation, and voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: medium — Proxy statements can reveal changes in leadership, compensation, or strategic direction that may impact the company's future performance and stock price.

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant
• STEMCELLS INC (company) — Former Company Name
• CYTOTHERAPEUTICS INC/DE (company) — Former Company Name

FAQ

Key Financial Figures

• $11,000 — Annual Meeting at an estimated cost of $11,000 plus expenses. The Company will pay the

Filing Documents

• def14a.htm (DEF 14A) — 741KB
• proxy_001.jpg (GRAPHIC) — 295KB
• proxy_002.jpg (GRAPHIC) — 256KB
• 0001493152-24-043762.txt ( ) — 1500KB

From the Filing

DEF 14A 1 def14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commissions Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12 MICROBOT MEDICAL INC. (Name of Registrant as Specified in its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 MICROBOT MEDICAL INC. 288 Grove Street, Suite 388 Braintree, MA 02184 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 17, 2024 Dear Shareholders: NOTICE IS HEREBY GIVEN, that the 2024 Annual Meeting of Shareholders (the “Annual Meeting”) of Microbot Medical Inc. (the “Company”) will be held at 11:00 A.M., Eastern Time on December 17, 2024 at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111. At the Annual Meeting, you will be asked to vote on: 1. The election of two Class III directors to the Board of Directors of the Company to serve until the 2027 Annual Meeting of Shareholders; 2. The approval of an amendment to the Company’s 2020 Omnibus Performance Award Plan, to increase the number of authorized shares of common stock reserved for issuance by 600,000, from 2,020,652 to 2,620,652; 3. The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2024; and 4. To transact such other and further business as may properly come before the meeting or any adjournment thereof. The Board of Directors has fixed the close of business on October 25, 2024 as the record date for determining shareholders who are entitled to receive notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. Your vote is important to us. Whether or not you intend to be present at the meeting, please sign and date the enclosed proxy card and return it in the enclosed envelope. Returning a proxy will not deprive you of your right to attend the Annual Meeting and vote your shares in person. The foregoing items of business are more fully described in the accompanying proxy statement. By Order of the Board of Directors, Harel Gadot Chairman, President and Chief Executive Officer Dated: November 6, 2024 Braintree, Massachusetts MICROBOT MEDICAL INC. 288 Grove Street, Suite 388 Braintree, MA 02184 PROXY 2024 ANNUAL MEETING OF SHAREHOLDERS December 17, 2024 This proxy statement and the accompanying proxy card is furnished in connection with the solicitation by the Board of Directors (the “Board”) of Microbot Medical Inc., a Delaware corporation (the “Company”), of proxies for use at the 2024 Annual Meeting of Shareholders (the “Annual Meeting”) to be held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, at 11:00 A.M., Eastern Time, on December 17, 2024, or at any adjournment or postponement thereof, for the purposes set forth in this proxy statement and the accompanying Notice of Annual Meeting of Shareholders. The Company is making available to you over the Internet or delivering paper copies of this proxy statement, a proxy card and the Company’s 2024 Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”), in connection with the Annual Meeting. The Company is using the rules of the Securities and Exchange Commission (“SEC”) that allow companies to furnish their proxy materials over the Internet. As a result, the Company is mailing to many of its stockholders a notice about the Internet availability of the proxy materials instead of a paper copy of the proxy materials. All stockholders receiving the notice will have the ability to access the proxy materials over the Internet, as well as to request a paper copy by mail or via email, free of charge, by following the instructions in the notice. The notice about the Internet availability of the proxy materials is first being mailed on or about November 6, 2024 to all shareholders of the Company entitled to vote at the Annual Meeting (the “Shareholders”). The Company will bear the cost of solicitation of proxies. Directors, officers and employees of the Company may solicit proxies by telephone, email, facsimile, in person or otherwise for no additional compensation. The Com

View Full Filing

View this DEF 14A filing on SEC EDGAR